Immune responses to respiratory syncytial virus (RSV) vaccines tended to fall short in older people with weakened immunity, a study found.
In 38 immunocompromised persons who received either the RSVPreF3-AS01E (RSVA-AS01E; Arexvy) or RSVpreF (Abrysvo) vaccine, preF IgG antibody titers rose a median 4.21-fold by 4 weeks — with 61% of the group meeting seroconversion, or criteria for immune response to RSV vaccination, reported William Werbel, MD, PhD, of the Johns Hopkins University School of Medicine in Baltimore, and colleagues.
“This study demonstrated heterogeneous antibody response to RSV vaccines among immunocompromised persons. In contrast to universal seroconversion and preF IgG fold rises greater…